/
LRMR
$3.20-$0.46 (-12.57%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$380.2M
104M shares
52-week range
$2.72 – $6.42
13% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Borrow rate
0.41%
Easy to borrow
Price (6 mo)
Loading chart…
Change$-6.62
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | $261.0K | $78.0K | $155.0K | $0 | $0 | $0 | $0 | $0 |
| Gross profit | −$261.0K | −$78.0K | −$155.0K | $0 | $0 | $0 | $0 | $0 |
| Gross margin | — | — | — | — | — | — | — | — |
| R&D | $49.5M | $20.8M | $31.3M | $38.4M | $24.3M | $27.7M | $73.3M | $154.2M |
| Operating income | −$62.7M | −$23.2M | −$42.8M | −$50.5M | −$36.5M | −$41.8M | −$90.9M | −$172.5M |
| EBITDA | −$60.8M | −$23.1M | −$42.6M | −$50.3M | −$35.0M | −$36.6M | −$80.3M | −$165.3M |
| Net income | −$61.4M | −$23.1M | −$42.3M | −$50.6M | −$35.4M | −$36.9M | −$80.6M | −$165.7M |
| Net margin | — | — | — | — | — | — | — | — |
| EPS (diluted) | -22.85 | -2.51 | -3.56 | -2.93 | -1.33 | -0.84 | -1.32 | -2.27 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $2M | $-1.66 | $-1.82–$-1.42 | 6 |
| 2027 | $58M | $-1.26 | $-1.77–$-0.85 | 5 |
| 2028 | $152M | $-0.57 | $-1.64–$1.73 | 5 |
| 2029 | $331M | $0.42 | $-0.01–$1.35 | 1 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$1.06
Price
$3.20
Implied downside
-67%
Peer comparison
Larimar Therapeutics, Inc. Common Stock
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell penetrating peptide technology platform. Its flagship product candidate, nomlabofusp, is a subcutaneously administered recombinant fusion protein designed to deliver frataxin (FXN) to the mitochondria of patients with Friedreich's ataxia (FA), a rare genetic disease characterized by insufficient production of FXN. The company also plans to use its intracellular delivery platform to design other fusion proteins to target additional rare diseases characterized by deficiencies in intracellular bioactive compounds.
www.larimartx.com- Employees
- 71
- IPO / List date
- May 29, 2020
- HQ
- BALA CYNWYD, PA
Held by traders on TradeandTell
No one on the platform currently holds LRMR.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 739,942 | $3.3M |
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded LRMR yet.
